A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants.

NCT ID: NCT04908124

Last Updated: 2021-07-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 183 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-01
• Study Completion Date: 2021-06-29

Brief Summary

This clinical investigation will look at the safety of five water based personal lubricants, and teir effectiveness the relief of intimate discomfort associated with vaginal dryness.

Detailed Description

This is an open label, five-arm, parallel-design clinical investigation determining the effectiveness and safety of five personal lubricants. This clinical investigation consists of two phases, a Tolerance Phase and a Treatment Phase, whereby a sub-set of subjects will enter both the Tolerance Phase followed by the Treatment Phase. The remaining subjects will enter the Treatment Phase only.

Conditions

Dyspareunia; Vaginal Dryness

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Lubricant A - Tolerance

A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.

This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.

Group Type: EXPERIMENTAL

Lubricant A

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant B - Tolerance

A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.

This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.

Group Type: EXPERIMENTAL

Lubricant B

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant C - Tolerance

A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.

This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.

Group Type: EXPERIMENTAL

Lubricant C

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant D - Tolerance

A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.

This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.

Group Type: EXPERIMENTAL

Lubricant D

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant E - Tolerance

A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.

This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.

Group Type: EXPERIMENTAL

Lubricant E

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant A - Treatment

A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.

This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase.

Group Type: EXPERIMENTAL

Lubricant A

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant B - Treatment

A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.

This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase.

Group Type: EXPERIMENTAL

Lubricant B

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant C - Treatment

A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.

This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase.

Group Type: EXPERIMENTAL

Lubricant C

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant D - Treatment

A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.

This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase.

Group Type: EXPERIMENTAL

Lubricant D

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Lubricant E - Treatment

A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.

This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase.

Group Type: EXPERIMENTAL

Lubricant E

Intervention Type: DEVICE

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Interventions

Lubricant A

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention Type: DEVICE

Lubricant B

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention Type: DEVICE

Lubricant C

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention Type: DEVICE

Lubricant D

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention Type: DEVICE

Lubricant E

Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention Type: DEVICE

Other Intervention Names

Durex Play Feel; Durex Naturals Moisture

Eligibility Criteria

Inclusion Criteria

1. Subject has provided written informed consent.

2. Subject is female and aged: 18 years to 65 years.

3. Female subject in a mutually monogamous heterosexual relationship (≥ 3 months) who is sexually active, defined as having sexual intercourse at least once a week.

4. Female subject of childbearing potential who is willing to use a highly effective method of contraception throughout the clinical investigation.

5. Female subject that agrees to have a gynaecological pelvic examination to ensure no significant disease findings and have intact skin and mucous in the test region assessed by the gynaecologist at all the relevant time points.

6. Subjects reporting mild to moderate vaginal dryness and dyspareunia during sex (when not using lubricant) in the past 3 months as confirmed on the Verbal Rating Scale (VRS).

1. Female subject in post-menopausal phase defined as having amenorrhea (absence of menstruation) for at least 12 months.

2. Female subject with premature menopause - surgical menopause or physiological menopause within the last 12 months or after having received chemotherapy.

Exclusion Criteria

1. Female subject who is pregnant, breast-feeding or trying to conceive.

2. Female subject who has previously experienced an irritant or allergic reaction to any personal lubricant, vaginal moisturiser or female hygiene product or known to suffer from any contact allergen and/or are allergic to the investigational product ingredients.

3. Female subject has urinary, vaginal infection (fungal, bacterial) or sexually transmitted infection as diagnosed by the investigator.

4. Female subject presenting signs of internal irritation, active psoriasis, eczema or other active skin disorder or with a history of skin disorder

5. Female subject presenting clinically abnormal findings other than irritation during the physical examination that will affect study outcome.

6. Female subject who has started, stopped or changed hormonal treatments (including contraceptives) during the previous 3 months prior to screening.

7. Female subject who has used any kind of topical histamine and/or topical hormonal based product for local treatment of vaginal dryness in the past 3 months.

8. Female subject with any medical conditions which in the opinion of the investigator could compromise the immune function.

9. Female subject taking steroid preparations, immune-suppressive drugs or any other medication which in the opinion of the investigator may affect the test results.

10. Female subject who has had any change to medication or treatment regimen for the treatment of diabetes mellitus during the previous 3 months prior to screening.

11. Female subject that will be unable to comply fully with the study requirements or unable to tolerate the procedures.

12. Female subject that have had a suspicion of malignancy or history of malignancy within the past 2 years.

13. Female subject who has had surgical cervical excision or vaginal and/or vulvar procedures in the previous year.

14. Female subject that has had a positive cervical screening examination for Human Papillomavirus (HPV) within the 3 years of the screening visit.

15. Female subject currently being treated with systemic medications or medicines that act locally in the vaginal area.

16. Female subject using vaginal douches and is unwilling to stop its use at least 2 weeks prior to screening and throughout the clinical investigation.

17. Female subject has changed contraceptive medication within the past 3 months or intending to change contraceptive medications.

18. Female subject has participated in another investigation within 3 months prior to screening.

19. Subject who is an employee at the site or a partner or first-degree relative of the Investigator.

20. Subject fails to satisfy the investigator of fitness to participate for any other reason.

1. Female subject that has had previous episodes of vaginal bleeding of unknown origin within the last 6 months of the screening visit.

2. Female subject showing vaginal prolapse and/or other medical conditions that could interfere with the study conduct and participation.

3. Female subject that have used any kind of systemic and/or local hormonal products for the treatment of vaginal dryness or any other vaginal condition in the 3 months prior to screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

proDERM GmbH

INDUSTRY

Sponsor Role: collaborator

Reckitt Benckiser Healthcare (UK) Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kirstin Deuble-Bente, Dr.

Role: PRINCIPAL_INVESTIGATOR

proDERM GmbH

Locations

proDERM GmbH

Hamburg, Pinneberg, Germany

Countries

Germany

Other Identifiers

5025002

Identifier Type: -

Identifier Source: org_study_id